Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14733MR)

This product GTTS-WQ14733MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14733MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14680MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ10367MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ1325MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ937MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ194MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ12135MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ4709MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ1982MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW